Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish R Patel

Showing results (71-80 of 167) with videos related to

Pageof 17
Sort By:
Cancer Chemotherapy and Pharmacology|January 25, 2020
Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesotheliomaZeeshan Ahmad, Blake A Jacobson, Mitchell W McDonald, et al.
Cancer|April 22, 2026
Disability-adjusted life-years from human papillomavirus-related oral cavity and pharynx cancers in US men, 2017-2021Harshank V Patel, Madison C Laird, Michael D Crone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>-</sup> Advanced Breast CancerErika P Hamilton, Manish R Patel, Anne C Armstrong, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 8, 2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesManish R Patel, William Donnellan, Michael Byrne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid TumorsRandy F Sweis, Georgina V Long, Adil Daud, et al.
Cancer|October 30, 2022
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumorsAung Naing, Alain P Algazi, Gerald S Falchook, et al.
Journal for Immunotherapy of Cancer|January 18, 2019
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trialUlrich Keilholz, Janice M Mehnert, Sebastian Bauer, et al.
Cancer Research Communications|June 22, 2026
Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumorsJaime R Merchan, Manish R Patel, Timothy P Cripe, et al.
Genes & Cancer|May 23, 2015
Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesotheliomaBlake A Jacobson, Esther Z Chen, Shaogeng Tang, et al.
Investigational New Drugs|August 7, 2019
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanomaShahneen Sandhu, Catriona M McNeil, Patricia LoRusso, et al.
Pageof 17

Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
Cancer Chemotherapy and Pharmacology|January 25, 2020
Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesotheliomaZeeshan Ahmad, Blake A Jacobson, Mitchell W McDonald, et al.
Cancer|April 22, 2026
Disability-adjusted life-years from human papillomavirus-related oral cavity and pharynx cancers in US men, 2017-2021Harshank V Patel, Madison C Laird, Michael D Crone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>-</sup> Advanced Breast CancerErika P Hamilton, Manish R Patel, Anne C Armstrong, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 8, 2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesManish R Patel, William Donnellan, Michael Byrne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid TumorsRandy F Sweis, Georgina V Long, Adil Daud, et al.
Cancer|October 30, 2022
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumorsAung Naing, Alain P Algazi, Gerald S Falchook, et al.
Journal for Immunotherapy of Cancer|January 18, 2019
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trialUlrich Keilholz, Janice M Mehnert, Sebastian Bauer, et al.
Cancer Research Communications|June 22, 2026
Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumorsJaime R Merchan, Manish R Patel, Timothy P Cripe, et al.
Genes & Cancer|May 23, 2015
Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesotheliomaBlake A Jacobson, Esther Z Chen, Shaogeng Tang, et al.
Investigational New Drugs|August 7, 2019
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanomaShahneen Sandhu, Catriona M McNeil, Patricia LoRusso, et al.
Pageof 17